Adverse Analytical Finding for Frank Schleck
July 18, 2012Earlier today, the UCI advised the Luxembourger rider Frank Schleck of an Adverse Analytical Finding (presence of the diuretic Xipamide based on the report from the WADA accredited laboratory in Châtenay-Malabry) in the urine sample collected from him at an in competition test at the Tour de France on 14 July 2012.
Mr. Schleck has the right to request and attend the analysis of his B sample. The UCI Anti-Doping Rules do not provide for a provisional suspension given the nature of the substance, which is a specified substance. However, the UCI is confident that his team will take the necessary steps to enable the Tour de France to continue in serenity and to ensure that their rider has the opportunity to properly prepare his defense in particular within the legal timeline, which allows four days for him to have his B sample analyzed. Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time. UCI Communications Services